Loading...
•
Sep 30, 2020
Twist Bioscience Q4 2020 Earnings Report
Twist Bioscience's revenue and orders reached record levels amidst the global pandemic. The company's core synthetic biology and next-generation sequencing (NGS) product lines were the primary drivers of success.
Key Takeaways
Twist Bioscience reported strong fourth-quarter and full-year fiscal 2020 financial results, with a significant increase in revenue and orders compared to the previous year. The company's synthetic biology and NGS product lines drove the overarching success.
Total revenues were $32.4 million for the fourth quarter of fiscal 2020, compared to $15.7 million for the same period of fiscal 2019.
Total orders received for the fourth quarter of fiscal 2020 were $42.7 million, compared to $20.0 million for the same period of fiscal 2019.
Net loss for the fourth quarter of fiscal 2020 was $24.3 million, or $0.54 per share, compared to $31.2 million, or $0.96 per share, for the fourth quarter of fiscal 2019.
Shipped products to approximately 2,200 customers in fiscal 2020, versus approximately 1,300 in fiscal 2019.
Twist Bioscience
Twist Bioscience
Forward Guidance
Twist Bioscience provided financial guidance for the full fiscal year 2021, expecting revenue in the range of $110 million to $118 million.
Positive Outlook
- Revenue expected in the range of $110 million to $118 million
- Revenue from Ginkgo Bioworks expected to be approximately $11 to $12 million
- Synbio revenue excluding Ginkgo Bioworks is expected to be in the range of $41 to $44 million
- NGS revenue is estimated to be in the range of $54 to $58 million
- Biopharma revenue is estimated to be approximately $4 million
Challenges Ahead
- Gross margin is expected to be approximately 32% for fiscal 2021
- Operating expenses including R&D and SG&A are expected to be $174 million for the year
- Net loss expected in the range of $136 million to $141 million to reflect our increased investments in our commercial organization and research and development activities
- R&D is expected to be approximately $60 million
- Capital expenditures are expected to be $30 million, including expansion into “Factory of the Future”